 | Up a level |
Cornely, O. A., Ostrosky-Zeichner, L., Rahav, G., Maher, R., Zeiher, B., Lee, M. and Perfect, J. (2015). Outcomes in Patients with Invasive Mold Disease Caused by Fusarium or Scedosporium spp. Treated with Isavuconazole: Experience from the VITAL and SECURE Trials. Mycoses, 58. S. 196 - 198. HOBOKEN: WILEY-BLACKWELL. ISSN 1439-0507
Marty, F. M., Perfect, J., Cornely, O. A., Mullane, K. M., Rahav, G., Lee, M., Ito, M., Maher, R., Zeiher, B. and Ostrosky-Zeichner, L. (2015). An open-label phase 3 study of isavuconazole (VITAL): focus on mucormycosis. Mycoses, 58. S. 198 - 200. HOBOKEN: WILEY-BLACKWELL. ISSN 1439-0507
Vehreschild, M. J. G. T., Vehreschild, J. J., Marty, F. M., Perfect, J., Ostrosky-Zeichner, L., Rahav, G., Zeiher, B., Lee, M., Maher, R., Lovell, C., Engelhardt, M. and Cornely, O. A. (2015). Primary treatment of invasive mucormycosis (IM) with isavuconazole (VITAL Study) or amphotericin formulations (FungiScopeTM): case matched analysis. Mycoses, 58. S. 197 - 198. HOBOKEN: WILEY-BLACKWELL. ISSN 1439-0507